BioFactura
Frederick
About BioFactura
BioFactura has developed the StableFast™ Biomanufacturing Platform, a novel system to rapidly generate stable NS0 cell lines for biopharmaceutical manufacturing. The elements of this system include a chemically-defined, serum- and cholesterol-free production medium and pre-adapted parental cells, modular expression vectors that utilize a patented selection strategy, and a proprietary growth supplement that permits rapid generation and cloning of cell lines. This platform is simple to use, fast, and productive. A clonal production cell line can be developed and scaled up to yield over one gram of product in less than eight weeks.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $76.2M
- Funding stage: Early Stage Venture
- Last round: Grant (Jul 2020)
- Website: biofactura.com
- Phone: (301)315-8002
Industries & Categories
Biotechnology, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/biofactura-9960 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.